UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13255

Cincotta, Anthony H

2023

Volltextzugriff (PDF)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet

International journal of molecular sciences, 2021-06, Vol.22 (11), p.6142

2021

Volltextzugriff (PDF)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

International journal of molecular sciences, 2022-08, Vol.23 (16), p.8851

2022

Volltextzugriff (PDF)

Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats

Diabetology and metabolic syndrome, 2021-01, Vol.13 (1), p.11-17, Article 11

2021

Volltextzugriff (PDF)

Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing

Endocrinology, diabetes & metabolism, 2020-07, Vol.3 (3), p.e00139-n/a

2020

Volltextzugriff (PDF)

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, diabetes & metabolism, 2020-01, Vol.3 (1), p.e00101-n/a

2020

Volltextzugriff (PDF)

1083-P: Bromocriptine-QR (BQR) Reduces Hypertriglyceridemia (HTG) in Hypertensive Type 2 Diabetes (T2D) Subjects

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Diabetology and metabolic syndrome, 2014-09, Vol.6 (1), p.104-104, Article 104

2014

Volltextzugriff (PDF)

Tyrosine Hydroxylase Knockdown at the Hypothalamic Supramammillary Nucleus Area Induces Obesity and Glucose Intolerance

Neuroendocrinology, 2024-01, Vol.114 (5), p.483-510

2024

Volltextzugriff (PDF)

1823-P: Bromocriptine (BC) Normalizes Elevated Expression of Liver Genes Involved in Fatty Acid Oxidation, Lipogenesis, Inflammation, and Endoplasmic Reticulum (ER) Stress and Glucose Intolerance of High-Fat/Sucrose Diet-Fed Rats

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2015-01, Vol.2015 (2015), p.1-13

2015

Volltextzugriff (PDF)

Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

Postgraduate medicine, 2017-05, Vol.129 (4), p.446-455

2017

Volltextzugriff (PDF)

Activation State of the Supramammillary Nucleus Regulates Body Composition and Peripheral Fuel Metabolism

Neuroscience, 2021-07, Vol.466, p.125-147

2021

Volltextzugriff (PDF)

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Diabetes care, 2010-07, Vol.33 (7), p.1503-1508

2010

Volltextzugriff (PDF)

Bromocriptine Mesylate Improves Glucose Tolerance and Disposal in a High-Fat-Fed Canine Model

American journal of physiology: endocrinology and metabolism, 2020-07, Vol.319 (1), p.E133-E145

2020

Volltextzugriff (PDF)

Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice

Neuroendocrinology, 2000-01, Vol.71 (1), p.68-78

2000

Volltextzugriff (PDF)

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

Expert review of endocrinology & metabolism, 2016-03, Vol.11 (2), p.113-148

2016

Volltextzugriff (PDF)

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

Postgraduate medicine, 2016-11, Vol.128 (8), p.761-769

2016

Volltextzugriff (PDF)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

Journal of the American Heart Association, 2012-10, Vol.1 (5), p.e002279-n/a

2012

Volltextzugriff (PDF)

1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

Diabetes care, 1996-06, Vol.19 (6), p.667-670

1996

Volltextzugriff (PDF)

Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Diabetes care, 2016-10, Vol.39 (10), p.1846-1846

2016

Volltextzugriff (PDF)

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents

Endocrine practice, 2012-11, Vol.18 (6), p.931-943

2012

Volltextzugriff (PDF)

Role of the Immune System in Mediating the Antitumor Effect of Benzophenothiazine Photodynamic Therapy

Photochemistry and photobiology, 1999-05, Vol.69 (5), p.575-581

1999

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats

Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

1083-P: Bromocriptine-QR (BQR) Reduces Hypertriglyceridemia (HTG) in Hypertensive Type 2 Diabetes (T2D) Subjects

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Tyrosine Hydroxylase Knockdown at the Hypothalamic Supramammillary Nucleus Area Induces Obesity and Glucose Intolerance

1823-P: Bromocriptine (BC) Normalizes Elevated Expression of Liver Genes Involved in Fatty Acid Oxidation, Lipogenesis, Inflammation, and Endoplasmic Reticulum (ER) Stress and Glucose Intolerance of High-Fat/Sucrose Diet-Fed Rats

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

Activation State of the Supramammillary Nucleus Regulates Body Composition and Peripheral Fuel Metabolism

756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Bromocriptine Mesylate Improves Glucose Tolerance and Disposal in a High-Fat-Fed Canine Model

Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice

Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA)

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents

Role of the Immune System in Mediating the Antitumor Effect of Benzophenothiazine Photodynamic Therapy

Suchergebnisse filtern